UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: September, 2006
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
September 21, 2006
By: /s/ David Skinner
---------------------------------------
David Skinner, Vice President,
General Counsel and Corporate Secretary
NEUROCHEM INC.
275 Armand-Frappier Blvd.
[NEUROCHEM (LOGO)] Laval, Quebec, Canada H7V 4A7
________________________________________________________________________________
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, Ph.D. Tel: (450) 680-4570
Vice President, Corporate Communications lhebert@neurochem.com
---------------------
NEUROCHEM TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE
LAVAL, Quebec, September 21, 2006 -- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announced today that on Tuesday, September 26, 2006, Dr. Francesco Bellini,
Chairman, President and Chief Executive Officer, will present Neurochem's
overall progress to date on its various drug development programs and the latest
regulatory developments at the UBS Global Life Sciences Conference to be held at
the Grand Hyatt New York, in New York (N.Y.). The presentation will take place
at 2:00 P.M. ET, in Ballroom B.
The corporate presentation will be available on the Company's Web site at
http://www.neurochem.com/Investor.htm#Presentation following Dr. Bellini's
speech.
A live audio Web cast of Neurochem's presentation can be accessed at
www.ibb.ubs.com. A replay of the presentation will begin three (3) hours after
the actual presentation time, and will be available until October 3, 2006.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics to address critical unmet medical needs. Eprodisate (Kiacta(TM)) is
currently being developed for the treatment of AA amyloidosis, for which the
Company received an approvable letter from the FDA in August 2006. Tramiprosate
(Alzhemed(TM)), for the treatment of Alzheimer's disease, is currently in Phase
III clinical trials in both North America and Europe and tramiprosate
(Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral
Amyloid Angiopathy, has completed a Phase IIa clinical trial.
TO CONTACT NEUROCHEM
For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1-877-680-4500 or visit our Web
site at www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, as well as other risks disclosed in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on the forward-looking statements
included in this news release. These statements speak only as of the date made
and Neurochem is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise.
Please see the Annual Information Form for further risk factors that might
affect the Company and its business.